Clinical trials: Solid Malignant Tumor
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
A Spiritual Health Intervention (PATH) for Improving Spiritual, Religious and Emotional Distress in Cancer Patients
This clinical trial tests the feasibility and effectiveness of a spiritual health intervention (Personal Archetypes Toward Healing Trial [PATH]) for improving spiritual, religious and existential distress in patients with cancer.
- Trial name
- NCT07545291
- Testing
- Spiritual Therapy, Survey Administration, Interview
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Fred Hutchinson Cancer Center
Metastatic Pancreatic Adenocarcinoma, Refractory Malignant Solid Neoplasm
Disulfiram and Chemotherapy in Treating Patients With Refractory Solid Tumors or Metastatic Pancreatic Cancer
This partially randomized phase I trial studies the side effects and best dose of disulfiram when given together with chemotherapy in treating patients with a solid tumor that does not respond to treatment (refractory) or…
- Conditions
- Metastatic Pancreatic Adenocarcinoma, Refractory Malignant Solid Neoplasm, Stage IV Pancreatic Cancer AJCC v8
- Trial name
- NCT02671890
- Testing
- Chemotherapy, Disulfiram, Gemcitabine Hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Mayo Clinic
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Self-Administered Relaxing Acupressure to Reduce Fatigue in Adolescent and Young Adult Cancer Survivors
This clinical trial tests the feasibility of self-administered relaxing acupressure on fatigue in adolescent and young adult (AYA) cancer survivors.
- Trial name
- NCT06442891
- Testing
- Acupressure Therapy, Internet-Based Intervention, Interview
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- University of Michigan Rogel Cancer Center
Solid Tumor, Adult
Phase 1/2a Study of ICT01 Plus Low Dose SC IL-2 in Patients With Advanced Solid Tumors
This is a phase I/IIa, two-part, open-label study to characterize the safety, tolerability, pharmacodynamics, and antitumor activity of ICT01 in combination with LDSC IL-2 in patients with advanced-stage solid tumors.
- Trial name
- EVICTION-2 (NCT05307874)
- Testing
- ICT01, Proleukin Injectable Product, Pembrolizumab injection
- Where
- 5 sites in France, Germany and 1 more
- Volunteers
- 56 people
- Sponsor
- ImCheck Therapeutics, an Ipsen company
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
RATIONALE: Diagnostic procedures, such as 3'-deoxy-3'-[18F] fluorothymidine (FLT) PET imaging, may help find and diagnose cancer.
- Conditions
- Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma
- Trial name
- NCT00935090
- Testing
- 3'-deoxy-3'-[18F]fluorothymidine
- Where
- United States
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Advanced Solid Tumors
Allogeneic WTX-212C in Advanced Solid Tumors
This is a multicenter, open-label, single-arm Phase I study to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity, and preliminary antitumor activity of allogeneic WTX-212C, an investigational allogeneic…
- Trial name
- WTX-212C-IIT (NCT07556653)
- Testing
- allogeneic WTX-212C
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Zhejiang Provincial People's Hospital
Solid Tumor Cancers, Lung Cancer
Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers
The purpose of this study is to find out what effects, a drug called ado-trastuzumab emtansine has on the patient and their cancer which is thought to be controlled by the abnormal HER2 gene.
- Conditions
- Solid Tumor Cancers, Lung Cancer, Bladder Cancer, Urinary Tract Cancers
- Trial name
- NCT02675829
- Testing
- ado-trastuzumab emtansine
- Where
- 7 sites in United States
- Volunteers
- 131 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
BRCA1 Gene Mutation, BRCA2 Gene Mutation
Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability
This phase II trial studies how well pembrolizumab works in treating participants with cancer that has spread to other places in the body, has come back or has spread to nearby tissues or lymph nodes.
- Conditions
- BRCA1 Gene Mutation, BRCA2 Gene Mutation, Locally Advanced Solid Neoplasm, Metastatic Malignant Solid Neoplasm
- Trial name
- NCT03428802
- Testing
- Laboratory Biomarker Analysis, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- Rutgers, The State University of New Jersey
Small-cell Lung Cancer, Neuroendocrine Carcinomas
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
This is Phase 1/2, multicenter, clinical study to evaluate the safety, efficacy, PK, and immunogenicity of IDE849 in subjects with DLL3-expressing tumors including SCLC.
- Conditions
- Small-cell Lung Cancer, Neuroendocrine Carcinomas, Solid Tumor Show to Express DLL3
- Trial name
- NCT07174583
- Testing
- IDE849, durvalumab, IDE161
- Where
- 13 sites in United States
- Volunteers
- 262 people
- Sponsor
- IDEAYA Biosciences
Solid Tumor, Non Small Cell Lung Cancer
GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 Therapy
This is a phase I/Ib, first-in-human (FIH), open-label, dose escalation and dose expansion study to evaluate the safety and tolerability, biological and clinical activities of GEN-001 in patients with locally advanced or…
- Conditions
- Solid Tumor, Non Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma
- Trial name
- NCT04601402
- Testing
- GEN-001, Avelumab
- Where
- 3 sites in United States
- Volunteers
- 11 people
- Sponsor
- Genome & Company
Tumors
Dose Escalation Study of SH U04722 in Solid Tumors
This study will evaluate the safety and tolerability of SH U04722 in patients with solid tumor cancers. In addition, this study will identify the recommended dose and administration schedule of SH U04722 for phase II development…
- Trial name
- NCT00375453
- Testing
- SH U04722
- Where
- 3 sites in Japan
- Volunteers
- 10 people
- Sponsor
- Bayer
Neuroblastoma, Sarcoma
Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma
Background: Pediatric solid tumors (Ewing's sarcoma, rhabdomyosarcoma, and neuroblastoma) are often difficult to cure with standard treatment.
- Conditions
- Neuroblastoma, Sarcoma, Rhabdomyosarcoma-Embryonal, Rhabdomyosarcoma- Alveolar
- Trial name
- NCT00923351
- Testing
- Tumor Purged/CD25 Depleted Lymphocytes, Tumor Purged/CD25 Depleted Lymphocytes with Tumor Lysate/KLH Pulsed Dendritic Cell Vaccine, rhIL-7
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Solid Neoplasm, Lymphoma
Safety and Tolerability of SYNB1891 Injection Alone or in Combination With Atezolizumab in Adult Participants
This Phase 1, open-label, multicenter, 2-arm study was designed to evaluate SYNB1891 when administered either as monotherapy (Arm 1) or in combination with atezolizumab (Arm 2) in participants with advanced/metastatic solid…
- Trial name
- NCT04167137
- Testing
- SYNB1891, Atezolizumab
- Where
- 6 sites in United States
- Volunteers
- 32 people
- Sponsor
- Synlogic
Cachexia; Cancer
Phase 2 Cachexia Clinical Trial to Evaluate the Efficacy and Safety of ASCA101
The goal of this clinical trial is to evaluate the efficacy and safety of ASCA101 for the treatment of Cachexia in solid tumor patients.
- Trial name
- NCT07168226
- Testing
- Active Comparator, ASCA101 24.32mg/kg, ASCA101 32.43mg/kg
- Where
- 6 sites in South Korea
- Volunteers
- 135 people
- Sponsor
- MetaFines
Malignant Solid Tumors
First in Human Study of 68Ga/64Cu-FAPI-XT117 PET/CT in Patients With Malignant Solid Tumors
This is the first-in-human study of 68Ga/64Cu-FAPI-XT117, which is an prospective, single-arm phase I clinical study.
- Trial name
- NCT05814835
- Testing
- 2-4 mCi 68Ga/64Cu-FAPI-XT117, 4-6 mCi 68Ga/64Cu-FAPI-XT117, 6-8 mCi 68Ga/64Cu-FAPI-XT117
- Where
- China
- Volunteers
- 14 people
- Sponsor
- Chinese PLA General Hospital
Tumor, Solid
Varian ProBeam Proton Therapy System China Clinical Trial (Hefei)
This study is prospective, two-center, single-arm objective performance criteria. This trial will be conducted in 2 clinical trial sites with a total of 47 subjects enrolled.
- Trial name
- ProBeam (NCT05463055)
- Testing
- Proton Therapy System (ProBeam)
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Varian, a Siemens Healthineers Company
Solid Tumor
A Study of Nivolumab in Combination With Ipilimumab in Chinese Participants With Previously Treated Advanced or Recurrent Solid Tumors
The purpose of this study is to evaluate the safety and effectiveness of Nivolumab in combination with Ipilimumab in Chinese participants with previously treated late stage cancer.
- Trial name
- NCT03195478
- Testing
- Nivolumab, Ipilimumab
- Where
- 12 sites in China
- Volunteers
- 37 people
- Sponsor
- Bristol-Myers Squibb
Advanced Solid Tumor
Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors
BIPAVE-001 is a Phase 1-2 study for evaluating the safety, pharmacokinetics (PK), and efficacy of AI-081 in solid tumors.
- Trial name
- BiPAVE-001 (NCT06635785)
- Testing
- AI-081
- Where
- 21 sites in United States
- Volunteers
- 387 people
- Sponsor
- OncoC4, Inc.
Tumor, Solid
Varian ProBeam Proton Therapy System Clinical Trial (Shandong)
This study is prospective, single-center, single-arm objective performance criteria. This trial will be conducted with a total of 47 subjects enrolled.
- Trial name
- NCT06340815
- Testing
- Radiation: Proton Therapy System (ProBeam)
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Varian, a Siemens Healthineers Company
Advanced Solid Tumor, Non-Small Cell Lung Cancer
GH21 Capsules for Advanced Solid Tumors: A Study on Safety and Early Results
Evaluate the safety and tolerability of GH21 in patients with advanced solid tumors. Estimate the maximum tolerated dose (MTD) in patients with advanced solid tumors.
- Conditions
- Advanced Solid Tumor, Non-Small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer
- Trial name
- NCT05183243
- Testing
- GH21 Capsule
- Where
- 9 sites in China
- Volunteers
- 68 people
- Sponsor
- Suzhou Genhouse Bio Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.